Pages that link to "Q96186614"
Jump to navigation
Jump to search
The following pages link to Nina P Paynter (Q96186614):
Displaying 50 items.
- Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption (Q21144958) (← links)
- Executive Summary: Heart Disease and Stroke Statistics--2012 Update: A Report From the American Heart Association (Q22241920) (← links)
- Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association (Q22306356) (← links)
- Association between a literature-based genetic risk score and cardiovascular events in women (Q24613965) (← links)
- Heart disease and stroke statistics--2011 update: a report from the American Heart Association (Q29547236) (← links)
- Heart disease and stroke statistics--2014 update: a report from the American Heart Association (Q29547691) (← links)
- Heart disease and stroke statistics--2012 update: a report from the American Heart Association (Q29547909) (← links)
- Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption (Q30303149) (← links)
- High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease (Q33737098) (← links)
- Socioeconomic status and incident type 2 diabetes mellitus: data from the Women's Health Study (Q34109872) (← links)
- Novel locus including FGF21 is associated with dietary macronutrient intake (Q34325630) (← links)
- Comparison of lifestyle-based and traditional cardiovascular disease prediction in a multiethnic cohort of nonsmoking women (Q34389051) (← links)
- Lipoprotein Subclass Abnormalities and Incident Hypertension in Initially Healthy Women (Q35157585) (← links)
- Estimating treatment effects for individual patients based on the results of randomised clinical trials (Q35252544) (← links)
- Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent (Q35448877) (← links)
- Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. (Q35583564) (← links)
- Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative (Q35884178) (← links)
- Tests of calibration and goodness-of-fit in the survival setting (Q36015031) (← links)
- Accumulation of metabolic cardiovascular risk factors in black and white young adults over 20 years (Q36085772) (← links)
- Performance of reclassification statistics in comparing risk prediction models (Q36090164) (← links)
- Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis (Q36674075) (← links)
- Clinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women (Q36752159) (← links)
- Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study (Q36807441) (← links)
- A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study (Q36892261) (← links)
- Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial (Q37031309) (← links)
- Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. (Q37069329) (← links)
- Prediction of incident hypertension risk in women with currently normal blood pressure (Q37165226) (← links)
- C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. (Q37363683) (← links)
- Cardiovascular disease risk prediction in women: is there a role for novel biomarkers? (Q37424605) (← links)
- Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis (Q37466366) (← links)
- Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association (Q38071269) (← links)
- Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial (Q38451132) (← links)
- Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use? (Q38740086) (← links)
- Relation of Alanine Aminotransferase Levels to Cardiovascular Events and Statin Efficacy (Q38851419) (← links)
- Adding tests to risk based guidelines: evaluating improvements in prediction for an intermediate risk group. (Q39412832) (← links)
- Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study (Q40298171) (← links)
- Coffee and sweetened beverage consumption and the risk of type 2 diabetes mellitus: the atherosclerosis risk in communities study (Q46597098) (← links)
- Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials (Q47579895) (← links)
- Clinical risk reclassification at 10 years (Q48270483) (← links)
- Metabolic Predictors of Incident Coronary Heart Disease in Women (Q49832342) (← links)
- Genetics and breast cancer risk prediction--are we there yet? (Q51646417) (← links)
- Executive Summary: Heart Disease and Stroke Statistics—2014 Update (Q57072448) (← links)
- Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study (Q57820905) (← links)
- Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in Women (Q58123836) (← links)
- Re.: "Association of small artery elasticity with incident cardiovascular disease in older adults: the Multi-ethnic Study of Atherosclerosis" (Q83114454) (← links)
- Comments on ‘Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers’ by M. J. Pencina, R. B. D'Agostino, Sr. and E. W. Steyerberg (Q83462740) (← links)
- Interpretation of Mendelian Randomization Studies and the Search for Causal Pathways in Atherothrombosis: The Need for Caution (Q84984913) (← links)
- Adverse Effects of Low-Dose Methotrexate: A Randomized Trial (Q89745202) (← links)
- Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative (Q90433403) (← links)
- Metabolomic profiles associated with all-cause mortality in the Women's Health Initiative (Q90941348) (← links)